Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Binod Dhakal, MD
Videos
Bridging Therapy Response Predicts Outcomes With Cilta-cel in Multiple Myeloma
04/13/2026
Binod Dhakal, MD
Binod Dhakal, MD, discusses results from the CARTITUDE-4 trial evaluating the impact of bridging therapy response in relapsed multiple myeloma refractory to lenalidomide.
Binod Dhakal, MD, discusses results from the CARTITUDE-4 trial evaluating the impact of bridging therapy response in relapsed multiple myeloma refractory to lenalidomide.
Binod Dhakal, MD, discusses...
04/13/2026
Oncology
Luciano Costa, MD
Videos
Ciltacabtagene Autoleucel Improves Long-Term Outcomes in Standard-Risk Relapsed/Refractory Multiple Myeloma
04/13/2026
Luciano J. Costa
Luciano Costa, MD, discusses long-term results from the CARTITUDE-4 trial evaluating ciltacabtagene autoleucel in patients with of standard-risk relapsed/refractory multiple myeloma.
Luciano Costa, MD, discusses long-term results from the CARTITUDE-4 trial evaluating ciltacabtagene autoleucel in patients with of standard-risk relapsed/refractory multiple myeloma.
Luciano Costa, MD, discusses...
04/13/2026
Oncology
Victor Jimenez Zepeda, MD
Videos
Advances for Patients With High-Risk Smoldering Multiple Myeloma
04/10/2026
Victor H. Jimenez Zepeda, MD
Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.
Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.
Victor Jimenez Zepeda, MD,...
04/10/2026
Oncology
Natalie Callander, MD
Videos
The Future of Cellular Therapies in Earlier Lines of Multiple Myeloma Treatment
03/06/2026
Natalie Callander, MD
Natalie Callander, MD, shares insights into progress of utilizing cellular therapies in earlier lines of therapy in the multiple myeloma treatment landscape.
Natalie Callander, MD, shares insights into progress of utilizing cellular therapies in earlier lines of therapy in the multiple myeloma treatment landscape.
Natalie Callander, MD, shares...
03/06/2026
Oncology
Tomotaka Suzuki, MD
Videos
Addition of Bortezomib to Daratumumab Maintenance Therapy Does Not Improve Progression-Free Survival in Transplant-Ineligible Multiple Myeloma: JCOG1911/ B-DASH Trial
02/27/2026
Tomotaka Suzuki, MD
According to results from a phase 3 trial, adding bortezomib to daratumumab maintenance did not improve PFS in transplant-ineligible patients with newly diagnosed multiple myeloma who responded to daratumumab, melphalan, prednisolone, and...
According to results from a phase 3 trial, adding bortezomib to daratumumab maintenance did not improve PFS in transplant-ineligible patients with newly diagnosed multiple myeloma who responded to daratumumab, melphalan, prednisolone, and...
According to results from a...
02/27/2026
Oncology
Dory Abelman, PhD, HBHSc
Conference Coverage
Ultra-Deep Whole Genome Sequencing of Cell-Free DNA Enhances MRD Detection and Risk Stratification in Multiple Myeloma
02/11/2026
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc,...
02/11/2026
Oncology
Luciano Costa, MD
Videos
Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial
01/30/2026
Luciano J. Costa
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported...
01/30/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use